Patents by Inventor Qingjian Wang

Qingjian Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES
    Publication number: 20240076364
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: December 20, 2022
    Publication date: March 7, 2024
    Applicant: FibroGen, Inc.
    Inventors: Al Y. LIN, Thomas B. NEFF, Noelynn A. OLIVER, William R. USINGER, Qingjian WANG, David A. YEOWELL
  • ANALYSIS ASSISTANT FOR DETERMINING EXECUTION INEFFICIENCIES IN DATAFLOW PROGRAMS
    Publication number: 20240078098
    Abstract: In a method, in response to an interface a computer-implemented analysis assistant initiates a presentation of inefficiency results, determined an efficiency analyzer based on a mapping of a dataflow program to execute on hardware of a computing system. The assistant receives an inefficiency included among the inefficiency results and composes formatted inefficiency results comprising a presentation format of the inefficiency to assist a developer of the dataflow program to interpret the inefficiency. The analysis assistant outputs the formatted inefficiency results to an interface, which can comprise an interface to output the formatted inefficiency results for use by the developer to improve the dataflow program in association with the inefficiency. In implementations the presentation can comprise an interactive presentation with a developer of the dataflow program. A computer program product and a computing system can implement the method.
    Type: Application
    Filed: November 8, 2023
    Publication date: March 7, 2024
    Applicant: SambaNova Systems, Inc.
    Inventors: Blaine RISTER, Qingjian LI, Bowen YANG, Junjue WANG, Chen LIU, Zhuo CHEN, Arvind SUJEETH, Sumti JAIRATH
  • METHOD AND SYSTEM TO DETERMINE EXECUTION INEFFICIENCIES IN DATAFLOW PROGRAMS
    Publication number: 20240069880
    Abstract: In a method a computer-implemented efficiency analyzer selects operators from an intermediate representation of a dataflow program. The operators are included in a mapping of the operators to hardware of a computing system to execute the dataflow program. Based on the mapping and a description of the hardware, the efficiency analyzer computes an execution metric associated with executing the operators on the hardware. Based on the execution metric and hardware description, the efficiency analyzer determines an inefficiency metric, and based on the inefficiency metric, the efficiency analyzer determines an inefficiency associated with the dataflow program. The computing system to execute the dataflow program can comprise a coarse grain computing system and the hardware can include a reconfigurable processor of the computing system. A computer program product and a computing system to a the dataflow program can implement the method.
    Type: Application
    Filed: November 8, 2023
    Publication date: February 29, 2024
    Applicant: SambaNova Systems, Inc.
    Inventors: Blaine RISTER, Qingjian LI, Bowen YANG, Junjue WANG, Chen LIU, Zhuo CHEN, Arvind SUJEETH, Sumti JAIRATH
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 11680047
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: June 20, 2023
    Assignee: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend
  • METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20210369702
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: August 5, 2021
    Publication date: December 2, 2021
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. KLAUS, Al Y. LIN, Thomas B. NEFF, Qingjian WANG, Volkmar GUENZLER-PUKALL, Lee A. FLIPPIN, Michael P. AREND, Alex MELEKHOV
  • CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES
    Publication number: 20210230259
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: September 8, 2020
    Publication date: July 29, 2021
    Applicant: FibroGen, Inc.
    Inventors: Al Y. LIN, Thomas B. NEFF, Noelynn A. OLIVER, William R. USINGER, Qingjian WANG, David A. YEOWELL
  • ENHANCED ERYTHROPOIESIS AND IRON METABOLISM
    Publication number: 20210107878
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 15, 2021
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 10927081
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 23, 2021
    Assignee: FIBROGEN, INC.
    Inventors: Stephen J Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend
  • CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES
    Publication number: 20190023778
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: October 10, 2018
    Publication date: January 24, 2019
    Applicant: FibroGen, Inc.
    Inventors: Al Y. LIN, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • METHODS FOR TREATING A NEUROLOGICAL DISORDER IN A SUBJECT USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) PROYL HYDROXYLASE
    Publication number: 20170312268
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: February 3, 2017
    Publication date: November 2, 2017
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. KLAUS, Al Y. Lin, Thamas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Lee A. Flippin, Michael P. Arend, Alex Melekhov
  • Connective Tissue Growth Factor Antibodies
    Publication number: 20160257740
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: May 25, 2016
    Publication date: September 8, 2016
    Applicant: FibroGen, Inc.
    Inventors: Al Y. Lin, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES
    Publication number: 20160024198
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: April 20, 2015
    Publication date: January 28, 2016
    Inventors: AL Y. LIN, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • Connective tissue growth factor antibodies
    Patent number: 9034643
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 19, 2015
    Assignee: FibroGen, Inc.
    Inventors: Al Y. Lin, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20150080425
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: July 16, 2014
    Publication date: March 19, 2015
    Applicant: FibroGen, Inc.
    Inventors: STEPHEN J. KLAUS, Al Y. Lin, Thomas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Lee A. Flippin, Michael P. Arend, Alex Melekhov
  • Methods For Reducing Blood Pressure
    Publication number: 20140163061
    Abstract: The present invention provides methods and medicaments for reducing blood pressure. Methods and medicaments for treating or preventing hypertension are also provided.
    Type: Application
    Filed: February 14, 2014
    Publication date: June 12, 2014
    Applicant: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Qingjian Wang, Ingrid Langsetmo Parobok, Guangjie Guo
  • Stabilization of Hypoxia Inducible Factor (HIF) Alpha
    Publication number: 20130245037
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Application
    Filed: May 17, 2013
    Publication date: September 19, 2013
    Applicant: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase
    Publication number: 20130203805
    Abstract: The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.
    Type: Application
    Filed: September 13, 2012
    Publication date: August 8, 2013
    Applicant: FIBROGEN, INC.
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Stabilization of hypoxia inducible factor (HIF) alpha
    Patent number: 8466172
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: June 18, 2013
    Assignee: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Methods for improving kidney function
    Patent number: 8318703
    Abstract: The invention relates to methods for improving renal (kidney) function. Methods for decreasing blood urea nitrogen (BUN), for increasing glomerular filtration rate (GFR), and for decreasing serum creatinine are also provided.
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: November 27, 2012
    Assignee: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Qingjian Wang, Thomas B. Neff
  • Diabetic nephropathy therapies
    Patent number: 8314059
    Abstract: The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: November 20, 2012
    Assignee: FibroGen, Inc.
    Inventors: Allan Flyvbjerg, Guangjie Guo, David Y. Liu, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang